Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of flufenidone plus tenofovir alafenamide in chronic hepatitis B with advanced fibrosis
ChiCTR2200065008Phase 2Recruiting
- Sponsor
- Beijing Friendship Hospital
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fluorofenidone and tenofovir alafenamide in Chronic Hepatitis B (CHB) and hepatic fibrosis (4 arms), sponsored by Beijing Friendship Hospital. Primary endpoint: Ishak fibrosis score at week 48. Started Oct 2022; status: recruiting.
02
Drugs
fluorofenidonetenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)hepatic fibrosis
Beyond the preview
Go deeper on ChiCTR2200065008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065008.